Gut Liver.
2010 Sep;4(3):357-362.
Efficacy of Rifaximin Compared with Ciprofloxacin for the Treatment of Acute Infectious Diarrhea: A Randomized Controlled Multicenter Study
- Affiliations
-
- 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. jooskim@snu.ac.kr
- 2Department of Internal Medicine, Inje University College of Medicine, Seoul, Korea.
- 3Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
- 4Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
- 5Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
- 6Department of Internal Medicine, Eulji University School of Medicine, Daejeon, Korea.
- 7Department of Internal Medicine, The Catholic University of Korea School of Medicine, Seoul, Korea.
- 8Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea.
- 9Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
Abstract
- BACKGROUND/AIMS
Ciprofloxacin has been widely prescribed for acute infectious diarrhea. However, the resistance to this drug is increasing. Rifaximin is a novel but poorly absorbed rifamycin derivative. This study evaluated and compared the efficacies of rifaximin and ciprofloxacin for the treatment of acute infectious diarrhea.
METHODS
We performed a randomized controlled multicenter study in Korea. Patients with acute diarrhea were enrolled and randomized to receive rifaximin or ciprofloxacin for 3 days. The primary efficacy endpoint was the time to last unformed stool (TLUS). Secondary endpoints were enteric wellness (reduction of at least 50% in the number of unformed stools during 24-hour postenrollment intervals), general wellness (subjective feeling of improvement), and proportion of patients with treatment failure.
RESULTS
Intent-to-treat analysis (n=143) showed no significant difference between the rifaximin and ciprofloxacin groups in the mean TLUS (36.1 hours vs 43.6 hours, p=0.163), enteric wellness (49% vs 57%, p=0.428), general wellness (67% vs 78%, p=0.189), or treatment failure rate (9% vs 12%, p=0.841). The adverse events did not differ significantly between the two groups.
CONCLUSIONS
These results suggest that rifaximin is as safe and effective as ciprofloxacin in the treatment of acute infectious diarrhea.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Efficacy and Safety of Short-term Administration of Rifaximin in the Treatment of Hepatic Encephalopathy
- Use of Oral Antibiotics in Elderly Gastrointestinal Patients
- Efficacy of Levofloxacin and Rifaximin based Quadruple Therapy in Helicobacter pylori Associated Gastroduodenal Disease: A Double-Blind, Randomized Controlled Trial
- Effect of Trimebutine and Rifaximin on Breath Hydrogen and Methane by Glucose Breath Test in Patients With Functional Bloating: A Randomized Double-blind Clinical Trial
- Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study
